Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana.

By M. Thigpen, Poloko M. Kebaabetswe, L. Paxton, Dawn K. Smith, C. Rose, Tebogo M. Segolodi, Faith L. Henderson, S. Pathak, F. Soud, K. Chillag and 14 more. New England Journal of Medicine, 2012

1,979 citations recorded by the source corpus.

Subfields: Emergency Medicine, Infectious Diseases

View Paper: https://www.semanticscholar.org/paper/1a78601dd3b552968be713829e4d3f041af8ceb3

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

1. V. Fonner
2. Sarah L Dalglish
3. C. Kennedy
4. G. Bolan
5. K. O'reilly
6. R. Baggaley
7. Florence M. Koechlin
8. M. Rodolph

Citations in the corpus

• Tenofovir-Based Preexposure Prophylaxis for HIV Infection among African Women (2015, neutral): “(%)¶ 68 (1) 12 (1) 15 (1) 16 (2) 14 (1) 11 (1)”
• On-Demand Preexposure Prophylaxis in Men at High Risk for HIV-1 Infection. (2015, neutral): “Any grade 3 or 4 event 19 (10) 15 (7) 0.”
• Sexually Transmitted Diseases Treatment Guidelines, 2015 (2015, background): “Preexposure Prophylaxis for HIV—Certain large, randomized, placebo-controlled trials examining daily oral antiretroviral preexposure prophylaxis (PrEP) with a fixed-dose combination of tenofovir disoproxil fumarate (TDF) and emtricitabine (FTC) have demonstrated safety (73) and a substantial reducti”
• Effectiveness and safety of oral HIV preexposure prophylaxis for all populations (2016, methodology): “Drug resistance Six trials measured and reported cases of TDF or FTC drug resistance, identified using standardized clinical genotypic laboratory assays [8,18,24,32,45,47].”